Open Nav

Nemus Bioscience, Inc.

  • Brian Murphy, Nemus Bioscience, Inc.

To provide an update on top 4 development programs

  • Date:Thursday, October 18
  • Time:2:45 PM - 3:00 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Nemus is a publicly traded (OTCQB:NMUS) biotech company developing derivatives of cannabinoid molecules for the treatment and management of diseases of urgent medical need, especially those involving vision such as glaucoma. The company is developing a prodrug of THC and an analog of CBD.
  • Company
  • Company HQ City:Long Beach, CA
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Market Cap:USD $43 million
  • Ticker:NMUS
  • Exchange:OTCQB
  • CEO/Top Company Official:Brian Murphy, MD
  • Year Founded:2014
  • Main Therapeutic Focus:Ophthalmology
  • Lead Product in Development :Prodrug of THC
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :3
  • Additional Information/Comments:The presentation will provide updates on cannabinoid drug development for treating glaucoma, retinal diseases, and resistant bacterial infections, particularly MRSA.
Brian Murphy
Nemus Bioscience, Inc.